GlaxoSmithKline plc made a bid to buy Redwood City, Calif.-based Genelabs Technologies Inc. for $1.30 per share, or about $57 million, in cash in a deal aimed at strengthening the London-based drug giant's product platform for hepatitis C virus (HCV) therapies. (BioWorld Today) Read More
